United Asset Strategies Inc. Cuts Position in Pfizer Inc. (NYSE:PFE)

United Asset Strategies Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 24.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 48,405 shares of the biopharmaceutical company’s stock after selling 15,681 shares during the quarter. United Asset Strategies Inc.’s holdings in Pfizer were worth $1,394,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the stock. Worth Asset Management LLC acquired a new stake in Pfizer during the 1st quarter valued at approximately $29,000. Briaud Financial Planning Inc acquired a new position in shares of Pfizer in the 3rd quarter worth approximately $30,000. GoalVest Advisory LLC grew its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 811 shares in the last quarter. Mizuho Securities Co. Ltd. bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $34,000. Finally, VisionPoint Advisory Group LLC lifted its holdings in shares of Pfizer by 52,350.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 1,047 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Monday. Argus cut Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price target on the stock. Finally, TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target on the stock. in a report on Thursday, January 4th. Twelve research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Trading Down 0.8 %

Shares of PFE opened at $25.69 on Wednesday. Pfizer Inc. has a 1 year low of $25.61 and a 1 year high of $41.33. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69. The stock has a 50 day simple moving average of $27.23 and a 200-day simple moving average of $28.79. The stock has a market cap of $145.47 billion, a PE ratio of 71.36, a PEG ratio of 1.18 and a beta of 0.61.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the prior year, the firm posted $1.14 EPS. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. On average, sell-side analysts predict that Pfizer Inc. will post 2.22 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.